Single-cell atlas analyses of NSCLC patients before and after αPD-1 therapy have revealed that patients enriched with Tregs in the tumor immune microenvironment exhibit a lower major pathological response rate, a phenomenon closely associated with an increased proportion of Tex-term and clonal expansion of CCR8+Tregs (48). The gene discussed is CCR8; the disease is non-small cell lung carcinoma.